

# unda®

# Muco coccinum

FLU PREVENTION AND TREATMENT

## Effective in flu prevention

*Clinically proven to be 88% effective in the prevention of influenza.<sup>1</sup>*

## Effective in primary flu-related symptom treatment

*Clinically proven to be 82% effective in the treatment of primary flu-related symptoms of chills, muscle aches and minor fever.<sup>2</sup>*




Every year in the United States, on average 5% to 20% of the population gets the flu, more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu-related causes.<sup>3</sup> In Canada, influenza results in an average of 20,000 hospitalizations and 4,000 deaths each year.<sup>4</sup> Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.

An influenza pandemic can occur when a new influenza virus subtype emerges and spreads easily among human beings. A new pandemic is considered inevitable but nobody can predict when and where it will emerge, who it will affect or how severe it will be. The consequences of the next pandemic may be large numbers of cases and deaths globally, as well as disruption of societies and economies (due to staff absenteeism and disruption of trade within and between countries).<sup>5</sup>

Flu viruses mutate constantly, producing new strains from year to year. The current flu vaccines are ineffective against any new types of flu as they do not provide protection against the latest flu strains. By the time the flu strain is obtained and manufactured, the particular virus may have mutated and new flu strains may have emerged, making the previous year's vaccines ineffective.

A strong immune system is paramount in fighting off any viruses minimizing the proliferation of bacterial and viral microorganisms.<sup>6</sup>

Percentage of effectiveness of Muco coccinum®



## RECOMMENDED DOSE:

### Adults and Children (12 years and older):

*Flu prevention:* One tablet every two weeks from the beginning of autumn to the end of winter.

*First sign of symptoms/acute:* One tablet under the tongue. Repeat, if necessary, every three to four hours for a maximum of three tablets daily.

*Risk Information:* If symptoms persist or worsen, consult a health care practitioner. If you are pregnant or breastfeeding do not use, unless directed by your health care practitioner.

1. Nollevaux MA et al. Observations cliniques en double aveugle contre placebo, de Mucococcinum 200K dans le traitement preventif des états grippaux. Altermedica Publishing.

2. Nollevaux MA et al. Intérêt du Mucococcinum 200K en pathologie grippale. Observations cliniques en pratique journalière. XXVIème Semaine. Homéopathe de Paris - 18 octobre 1990 - Altermedica Publishing

3. Centers for Disease Control and Prevention Website ([www.cdc.gov](http://www.cdc.gov)), April 2009

4. Public Health Agency of Canada Website ([www.publischealth.gc.ca](http://www.publischealth.gc.ca)), April 2009

5. World Health Organization Website (<http://www.euro.who.int>), April 2009

6. Balch JF, Balch PA. Prescription for Nutritional Healing. New York: Avery Publishing Group; 1997.

This information is for professional use only and is not meant to diagnose, treat, cure, prevent any disease or replace traditional treatment, and has not been evaluated by the FDA or Health Canada.

Copyright © 2009 Seroyal. All rights reserved. No part of this information may be used or reproduced in any form or by any means, or stored in a database or retrieval system, or be distributed or replicated without express permission of Seroyal. Making copies of any part of this information for any purposes other than your own personal use is a violation of copyright law.

Two separate clinical studies confirm that Muco coccinum® is:

- **Clinically proven to be 88% effective in the prevention of influenza<sup>1</sup>**
- **Clinically proven to be 82% effective in the treatment of primary flu-related symptoms of chills, muscle aches and minor fever<sup>2</sup>**

### 1) Synopsis of first trial – Treatment of influenza<sup>1</sup>

The first study was an open label trial from September 1988 to April 1989, which entailed daily patient observations by a member of a medical team.

From the onset, the patient's flu-related symptoms were documented. Muco coccinum® was given to all to take on its own, or with adjunctive therapy such as single homeopathic remedies, antibiotics, vitamin C, oligotherapy, etc. which would be noted by the doctor. The dosage was one tablet in the morning and one at bedtime.

Excluded from the study were patients who were being treated with cortisone, immuno-depressants, MAO inhibitors or tricyclic antidepressants, or if being treated for AIDS, lupus and other confirmed collagenose.

After the third day of the therapy, the progression of the patient's symptoms were recorded by the medical staff. A total of 177 clinical observations were accumulated of which 50 were excluded as they were on drug-related therapies. The other 127 observations were retained for further study.

This open label study demonstrated that Muco coccinum® was very effective at 82.05% in the treatment of primordial flu symptoms such as chills, myalgias and fevers, and obtained 75% efficacy for secondary symptoms such as coryza and sore throats.

Based on the strong positive results of this study, a double-blind, placebo-controlled trial was conducted to further validate the efficacy of Muco coccinum® in the prevention of influenza.

### 2) Synopsis of second trial – Prevention of influenza<sup>2</sup>

The five-month study, from November 1989 to March 1990, was conducted on 200 subjects of which 100 subjects were in the treatment group and the other 100 subjects in placebo group.

The subjects selected were nursing students and medical teachers from a nursing school, as this population has a high risk of contamination due to its frequent and daily contact with patients in hospital settings. The age of the subjects were recorded under three categories: less than 25 years old, between 26-55 years old, and over 56 years old. The dosage given was one tablet every 15 days.

Out of the 100 clinical observations from the treatment group, 99 were retained; whereas 92 out of the 100 clinical observations were retained from the placebo group, for a total of 191 observations that were kept for a statistical study.

Results showed Muco coccinum® was 88% effective in the prevention of flu as compared to a 64% flu prevention effectiveness rate for the placebo group.

1. Nolleaux MA et al. Intérêt du Mucococcinum 200K en pathologie grippale. Observations cliniques en pratique journalière. XXVIème Semaine. Homéopathique de Paris - 18 octobre 1990 - Altermedica Publishing.

2. Nolleaux MA et al. Observations cliniques en double aveugle contre placebo, de Mucococcinum 200K dans le traitement préventif des états grippaux. Altermedica Publishing.